


The following listing of claims replaces all prior versions, and listings, of claims in the application:

IN THE CLAIMS:

1. (Currently amended) A compound of the formula



wherein

x is from 0 to 2;

R^1 is selected from the group consisting of hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkyl amino (wherein the alkyl group is optionally substituted by halo)


R^2 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl and cycloalkylalkyl, wherein alkyl moieties are optionally substituted by halo, and aryl groups are optionally substituted by C_1 to C_4 alkyl, C_1 to C_4 alkoxy and halo,

R^3 is absent when $-Y-Z-R^2$ is attached to N, or R^3 is selected from the group consisting of H, C_1 to C_7 alkyl and benzyl, when


$-Y-Z-R^2$ is not attached to N;

Y is C_2 to C_{10} alkylene, in which one non-terminal carbon atom may be replaced by O; and

Z is



wherein R^5 , R^6 and R^7 are independently H, aryl (C_1 to C_3) alkyl or cycloalkyl (C_1 to C_3) alkyl optionally substituted by halo, and Q is H or methyl, or Q is linked to R^5 or R^7 to form a five-membered ring or Q is linked to R^2 to form a six-membered ring, provided that when Z is



at least one of R^5 and R^7 is aryl(C_1 to C_3)alkyl or cycloalkyl(C_1 to C_3)alkyl, optionally substituted by halo;
or a pharmaceutically acceptable salt thereof.